The mechanism of action of lenvatinib (lenvatinib) in the treatment of cancer

Lenvatinib (Lenvatinib) is an oral multi-kinase inhibitor that is widely used to treat various types of malignant tumors, including thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, etc. Its therapeutic effect is mainly achieved through the following mechanisms:

1.Inhibit angiogenesis: Lenvatinib inhibits the activity of multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), basic fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), etc. These receptors play a key role in the process of tumor angiogenesis. By inhibiting their activity, Lenvatinib can block the formation of new blood vessels in tumors, thereby inhibiting tumor growth and spread.

2.Inhibit tumor cell proliferation: In addition to affecting angiogenesis, Lenvatinib can also directly act on tumor cells by inhibiting the activity of various RTKs, such as FGFR, PDGFR, etc., thereby interfering with the proliferation signaling pathways of tumor cells and inhibiting the proliferation and growth of tumor cells.

3.Inducing tumor cell apoptosis: Lenvatinib can also induce tumor cell apoptosis by regulating apoptosis-related signaling pathways, such as PI3K/AKT, MAPK and other pathways, thereby promoting tumor cell death.

4.Inhibition of tumor cell migration and invasion: The anti-tumor effect of Lenvatinib also includes inhibiting the migration and invasion ability of tumor cells, thereby blocking tumor metastasis and spread.

In summary, Lenvatinib (Lenvatinib) It simultaneously affects tumor cells and the tumor microenvironment through multiple mechanisms of action, thereby achieving therapeutic effects on multiple types of cancer. Its unique targeting and ability to inhibit multiple signaling pathways make it one of the important drugs in current tumor treatment. However, Lenvatinib is also associated with certain side effects, such as high blood pressure, fatigue, loss of appetite, etc. Therefore, the patient's physical condition needs to be closely monitored during use and corresponding adjustments and management should be made as needed.